Navigation Links
Aratana Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/13/2013

KANSAS CITY, Kan. and BOSTON, Nov. 13, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX) today announced its third quarter 2013 financial results and recapped its development activities.

"This has been a very productive quarter for Aratana," said Dr. Steven St. Peter, President and CEO of Aratana Therapeutics. "We have continued to move forward in establishing ourselves as the premier pet therapeutics company."

The quarter was highlighted by the signing of two option agreements, and the continued progress of the company's development programs. In mid-October, Aratana acquired Vet Therapeutics, a San Diego-based biologics company whose first products are being developed as treatments for lymphoma in dogs and cats, one of the most prevalent cancers in our pets.

Development Programs and Upcoming Milestones

  • AT-001 Dog: Topline results from dose-ranging field study expected in the second half of November 2013; continue to anticipate U.S. approval in 2016
  • AT-001 Cat: Pursuing a chronic pain claim
  • AT-002 Dog: Agreement on pivotal study design reached with Center for Veterinary Medicine (CVM); pivotal field study effectiveness protocol submitted to CVM for review; expect to initiate pivotal study in late 2013; continue to anticipate U.S. approval in 2016
  • AT-002 Cat: Selected three week treatment term and weight gain and/or control claim for further proof of concept work; final formulation selected; expect results 1H 2014
  • AT-003 Dog: Continued dose-ranging study in laboratory dogs; anticipate discussions with the CVM on development program in late 2013; continue to anticipate U.S. approval in 2016
  • AT-003 Cat: Initiated dose-ranging study in laboratory cats
  • Option Programs: Evaluation
    '/>"/>

  • SOURCE Aratana Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Aratana to Participate in Leerink Swanns November Management Access Days
    2. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
    3. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
    4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
    5. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
    6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
    7. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
    8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
    9. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
    10. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
    11. Aratana Therapeutics names Wendy Yarno to its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
    (Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
    (Date:8/29/2014)... Does your doctor know what you,re smoking?  Chances are, probably ... the over 112,000 currently registered patients under Colorado,s ... roughly 20,300+ active physicians listed with the Colorado Dept of ... though a poll in February 2014 showed 51% of ... "With marijuana legalization underway, every doctor needs ...
    Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
    ... Inc. (NYSE AMEX: ULU ), a ... portfolio of wound management and oral care products, today ... with Ironridge Global BioPharma and its affiliates ("Ironridge"), under ... certain conditions, to purchase common and preferred stock totalling ...
    ... N.J., Sept. 15, 2011 Soligenix, Inc. (OTCBB: ... company, announced that an independent Data Safety Monitoring ... for safety and futility for Soligenix,s confirmatory Phase ... of beclomethasone dipropionate (BDP) in acute gastrointestinal Graft-versus-Host ...
    Cached Medicine Technology:ULURU Inc. Enters Into Strategic Financings of Up to $1.6 Million at a Premium to Current Share Price 2ULURU Inc. Enters Into Strategic Financings of Up to $1.6 Million at a Premium to Current Share Price 3Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 2Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 3Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 4Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 5Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 6
    (Date:9/1/2014)... shows on TV may be bad for your waistline, a ... while watching action films and programs than something less exciting, ... if you,re watching an action movie while snacking your mouth ... the Cornell Food and Brand Lab, said in a university ... is, the more you will eat." The study included ...
    (Date:9/1/2014)... (PRWEB) September 01, 2014 An operating ... a hospital for performing surgical operations. An operating room ... tables, surgical booms, operating room lights, imaging displays as ... a report by Transparency Market Research, a U.S.-based market ... to reach USD 4.5 billion by 2019. , ...
    (Date:9/1/2014)... 01, 2014 The B-cell non-Hodgkin’s Lymphoma ... six major markets (the US, France, Italy, Germany, Spain ... $5.41 billion by 2018. , The competitive landscape in ... Germany, Spain and the UK is poised to undergo ... of the four largest B-cell NHL indications, which includes ...
    (Date:9/1/2014)... 1 September 2014: Permanent atrial fibrillation (AF) doubles the ... research in more than 6 000 patients presented at ... The findings suggest that a simple clinical assessment of ... estimate stroke risk. , Ischaemic stroke is the second ... a million deaths and many more disabled patients each ...
    (Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
    Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3
    ... ... will help you transform the way employees engage inside and outside of the workplace. ... Milwaukee, Wisc. (PRWEB) February 1, ... event “Aligning the Corporate and Personal Brand,” hosted by Loyola University in Chicago. ...
    ... who took the course were more likely to delay having ... who took abstinence-only sex education classes were more likely to ... study, some 662 black 6th- and 7th-grade students, ranging in ... 12, participated in classes held on Saturdays at four Philadelphia ...
    ... memory skills after 12 weeks of treatment, researchers report ... after a stroke may help repair the damaged brain ... Little has been shown to help the brain restore ... initial stroke treatment. But a University of Iowa study ...
    ... Surprise finding may have implications for labor anesthesia, orthopedics and ... One of the holy grails of local anesthesia is the ability ... not affecting motor function. Now, researchers at Children,s Hospital Boston have ... it proves to work in humans as well as it did ...
    ... , , Rare, but serious, liver disorder ... 1 The U.S. Food and Drug Administration today announced ... has been reported in some HIV patients taking Videx/Videx EC ... is an antiretroviral medicine first approved by the FDA in ...
    ... , Proposed projects will combat global ... Kiwanis International is searching for its next global cause, ... Service Project finalists: Global Network for Neglected Tropical Diseases for ... the Canadian Red Cross for their joint malaria proposal; and ...
    Cached Medicine News:Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 3Health News:Antidepressants After Stroke May Boost Mental Ability 2Health News:Antidepressants After Stroke May Boost Mental Ability 3Health News:Anesthetic Approach Stops Pain Without Affecting Motor Function 2Health News:Anesthetic Approach Stops Pain Without Affecting Motor Function 3Health News:FDA Announces Safety Risk Associated with HIV Drug 2Health News:Kiwanis Selects Three Finalists for Worldwide Service Project 2Health News:Kiwanis Selects Three Finalists for Worldwide Service Project 3Health News:Kiwanis Selects Three Finalists for Worldwide Service Project 4
    Designated most popular model or size. Double-ended. 2 mm wide....
    Designated most popular model or size. Slightly angled, 2 mm wide....
    4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
    Desmarres Infant Retractor...
    Medicine Products: